Click Therapeutics Awarded National Institutes of Health (NIH) Grant for Clickotine® Digital Therapeutic Study

Published: May 08, 2018

NEW YORK--(BUSINESS WIRE)-- Click Therapeutics, Inc., has been awarded a National Institutes of Health (NIH) Small Business Innovation and Research (SBIR) grant through the National Institute of Drug Abuse (NIDA). The Phase 1 SBIR project, entitled “Clinical trial of an innovative digital therapeutic for smoking cessation with biochemical verification” will further establish the efficacy of Clickotine, Click’s digital therapeutic for smoking cessation. Clickotine will be compared head to head with the National Cancer Institute’s (NCI) smoking cessation app QuitGuide. The SBIR project will also establish the feasibility of administering remote biochemical verification of smoking cessation using an exhaled carbon monoxide assessment.
 
Brian Iacoviello, Ph.D., Director of Scientific Affairs at Click Therapeutics, and the Principal Investigator on the SBIR grant, notes, “Securing this grant is another inflection point for Click. Click has already demonstrated the capacity to conduct robust clinical research on its products and has now shown the ability to have this research federally funded. Moreover, successfully executing this SBIR project holds the potential to significantly grow the value and utility of Clickotine as a digital therapeutic for smoking cessation.”
 
Chief Commercial Officer Joel Sangerman added, “Since launching Clickotine at the end of 2017, we have agreements to deploy Clickotine to over 30 payers and employers, many of which we have engaged in value-based purchasing agreements. This NIH award will help us extend our pay-for-performance programs with more precise outcome measures and payment models to better serve our customers and the over seven million beneficiaries covered by Clickotine."
 
About Click Therapeutics
 
Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults. For more information, visit ClickTherapeutics.com or Clickotine.com.

Information reported in this press release was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number R43DA045395. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Contacts

Click Therapeutics, Inc.
Media:
Sarah Jackson
sarah@clicktherapeutics.com
or
Investors:
Ted Silver
ted@clicktherapeutics.com

 
 

Source: Click Therapeutics, Inc.

Back to news